4.Which of the following indications related to epigenetic modulators has NOT been approved by FDA?

A. Panobinostat as monotherapy for treatment of refractory multiple myeloma (MM)

B. Panobinostat in combination with bortezomib and dexamethasone for treatment of relapsed MM

C. Belinostat as monotherapy for treatment of relapsed or refractory PTCL

D. Ivosidenib as monotherapy for treatment of patients with newly diagnosed or relapsed/refractory AML with isocitrate dehydrogenase 1 (IDH1) mutation